93793-83-0

Basic information

• Product Name: Roxatidine acetate hydrochloride
• Synonyms: 2-acetoxy-n-[3-[3-(1-piperidinomethylphenoxy]propyl]acetamide hydrochloride;2-(acetyloxy)-n-(3-(3-(1-piperidinylmethyl)phenoxy)propyl)-acetamidmonoh;2-acetoxy-n-(3-(m-(1-piperidinylmethyl)phenoxy)propyl)acetamidehydrochloride;2-hydroxy-n-(3-(m-(piperidinomethyl)phenoxy)propyl)-acetamidacetate(ester;2-hydroxy-n-(3-(m-(piperidinomethyl)phenoxy)propyl)acetamideacetate(ester);aceroxatidinehydrochloride;acetamide,2-hydroxy-n-(3-(m-(1-piperidinylmethyl)phenoxy)propyl)-,acetate,;tzu0460
• CAS NO: 93793-83-0
• Molecular Formula: C₁₉H₂₈N₂O₄*ClH
• Molecular Weight: 384.89756
• EINECS: 1308068-626-2
• Product Categories: Miscellaneous Biochemicals;Amines;Aromatics;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;MEFOXIN;Other APIs
• Mol File: 93793-83-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 145-146°
• Boiling Point: 537.3 °C at 760 mmHg
• Flash Point: 278.7 °C
• Appearance: /
• Vapor Pressure: 1.29E-11mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Merck: 14,8274
• CAS DataBase Reference: Roxatidine acetate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Roxatidine acetate hydrochloride(93793-83-0)
• EPA Substance Registry System: Roxatidine acetate hydrochloride(93793-83-0)

Safety Data

• RTECS: AC3855000
• Hazardous Substances Data: 93793-83-0(Hazardous Substances Data)

Usage

Description

Roxatidine acetate hydrochloride, also known as ALTAT, is a competitive histamine H2 receptor antagonist that differs significantly in structure from other marketed agents such as cimetidine, ranitidine, and famotidine. It is a white solid that, upon oral absorption, is rapidly converted to its active metabolite, roxatidine. By inhibiting the binding of histamine to H2 receptors, roxatidine reduces both intracellular cAMP concentrations and gastric acid secretion by parietal cells. This makes it useful in the treatment of gastric, duodenal, and anastomotic ulcers, Zollinger-Ellison syndrome, and peptic esophagitis.

Uses

Used in Pharmaceutical Industry:
Roxatidine acetate hydrochloride is used as a histamine H2-receptor antagonist for inhibiting gastric acid secretion. It serves as an antiulcer agent, helping in the treatment of various gastrointestinal conditions such as gastric, duodenal, and anastomotic ulcers, Zollinger-Ellison syndrome, and peptic esophagitis. Its unique structure and mechanism of action make it a valuable addition to the therapeutic options available for these conditions.

Originator

Teikoku Hormone (Japan)

InChI:InChI=1/C19H28N2O4.ClH/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21;/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23);1H

Upstream product

• 127-08-2 potassium acetate 
• 108441-34-5 N-<3-<3-(1-piperidinylmethyl)phenoxy>propyl>chloroacetamide 
• 110-89-4 piperidine 
• 73279-04-6 3-[1-piperidinylmethyl]phenol 
• 73278-98-5 N-<3-<3-(1-piperidinylmethyl)phenoxy>propyl>amine 
• 100-83-4 meta-hydroxybenzaldehyde 
• 97900-88-4 C₁₇H₂₆N₂O₃*(x)ClH 
• 108-24-7 acetic anhydride 
• 93138-55-7 3-(piperidinomethyl)benzenamine 
• 78273-80-0 2-hydroxy-N-[3-[3-(piperidinomethyl)phenoxy]propyl] acetamide 
• 99-61-6 3-nitro-benzaldehyde 
• 59507-46-9 3-(piperidin-1-ylmethyl)nitrobenzene 
• 619-25-0 3-Nitrobenzyl alcohol 
• 26646-51-5 3-(m-tolyloxy)propylamine 

Downstream Products

• 1338084-91-5 C₁₉H₂₈N₂O₄*C₄₂H₇₀O₃₅ 

Relevant articles and documents

A preparation method for rosacea acetate hydrochloride

The present invention relates to the field of pharmaceutical preparation technology, in particular to a method for preparing rosatidine acetate hydrochloride. The present invention adopts m-hydroxybenzoic acid as a starting material, a wide range of sources, inexpensive, and it can be prepared by oxidation of m-hydroxytoluene, without involving a toxicity warning structure and nitrosamine impurities; at the same time, in this preparation process only involves a genotoxic warning structure substance, reducing the risk of medication of subsequent drugs.

Preparation method of roxatidine acetate hydrochloride

The invention relates to a preparation method of roxatidine acetate hydrochloride. The preparation method comprises the following steps: step 1, dissolving m-cresol and 3-chloropropylamine hydrochloride into a reaction solvent according to a certain ratio, carrying out a reaction in the presence of an alkali, extracting after the reaction, and concentrating after simple purification to obtain an intermediate 1; 2, dissolving the intermediate 1 and an alkali in a reaction solvent according to a certain ratio, adding acetoxyacetyl chloride in a dropwise manner at a low temperature, and extracting and concentrating after the reaction of the intermediate 1 is finished to obtain an intermediate 2; 3, carrying out a bromination reaction on the intermediate 2 and N-bromosuccinimide, and directlycarrying out water washing extraction to obtain an intermediate 3; 4, carrying out a reaction on the intermediate 3 and excessive piperidine in a solvent, concentrating, extracting with dichloromethane, drying, and further purifying with acetic anhydride to obtain roxatidine acetate; 5, dissolving the intermediate 3 in acetone, adding hydrochloric acid in a dropwise manner to form a salt, filtering, and drying; and 6, mixing with absolute ethyl alcohol, filtering, carrying out cooling crystallization, and drying to obtain the roxatidine acetate hydrochloride.

Preparation method of roxatidine acetate hydrochloride

The invention discloses a preparation method of roxatidine acetate hydrochloride. The preparation method is characterized by adopting m-hydroxybenzaldehyde and piperidine as raw materials for carrying out chemical synthesis under the conditions of microwave radiation and high frequency ultrasonic wave, so that the product yield is improved, the reaction time is shortened, the cost is reduced, the product purity is improved, the total impurities are reduced, and an ideal effect is achieved.